Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

In the latest trading session, Moderna (MRNA) closed at $30.41, marking a -2.38% move from the previous day. This move lagged ...

The day after Christmas is supposed to be one of the better days of the year. It’s not looking like that right now. After trading higher to start the day, the S&P 500 has dipped 0.04%, while the Dow ...

Health care stocks followed the main indexes in a post-holiday decline, before bouncing back to close slightly higher, among a lack of market-moving news and data points.

A potentially fatal inflammatory disorder has been connected to the COVID-19 vaccine, and one researcher told the Daily Mail ...

Follow live coverage of the stock market's moves today. The Dow Jones Industrial Average, S&P 500, and Nasdaq are all flat in morning trading hours.

CytomX Therapeutics, Inc. is downgraded to Hold ahead of key CX-2051 Phase 1 expansion data in 1Q26. Learn more about CTMX ...

With President Donald Trump back in the White House in 2025, it’s no surprise that he dominates the FactCheck.org year-end ...

Moderna posted 0% earnings growth in the latest quarterly report. Revenue increased -45%. Moderna earns the No. 356 rank among its peers in the Medical-Biomed/Biotech industry gro ...

Easing hot flashes, treating rare genetic diseases and a made-in-Canada vaccine among the year’s notable developments ...

The appointment of a fervent vaccine opponent — Robert F. Kennedy Jr. — as secretary of the Department of Health and Human ...